Given that severe COVID‐19 is characterized by high‐grade systemic inflammation with elevated IL‐6 levels, it is likely that such mechanisms are also operative in this condition, possibly contributing to the higher risk of AVB observed.36, 37 However, while disease‐induced myocardial damage and cardiac toxicity of repurposed “off‐label” medications gained great attention as potential pathogenic factors,10, 11, 12, 13, 14, 15 at the moment there are no studies which have specifically evaluated the impact of IL‐6 elevation on COVID‐19‐associated conduction disturbances. Here, IL6 is linked to COVID-19.